NRANSMITTAL LETTER Docket No. JUL 2 1 2006 General - Patent Pending) 19710 In Re Application Of lfi Biedermann et al. Application No. Filing Date Customer No. Group Art Unit Confirmation No. Examiner 09/595,218 June 16, 2000 Zinna Northington Davis 23389 1625 2204 Title: CYCLIC IMIDE-SUBSTITUTED PYRIDYLALANE, ALKENE, ALKINE, CARBOBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS **COMMISSIONER FOR PATENTS:** Transmitted herewith is: Revocation of Power of Attorney with New Power of Attorney and Change of Correspondence Address Statement Under 37 C.F.R. 3.73 (b) with copy of original Assignment attached in the above identified application. No additional fee is required. A check in the amount of is attached. The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. Charge the amount of Credit any overpayment. Charge any additional fee required. ☐ Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Dated: July 17, 2006 Mark J.' Cohen Registration No. 32.211 Scully, Scott, Murphy & Presser, P.C. I hereby certify that this correspondence is being 400 Garden City Plaza, Suite 300 denosited with the United States Postal Service with sufficient postage as first class mail in an envelope Garden City, New York 11530 addressed to the "Commissioner for Patents, P.O. Box (516) 742-4343 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on July 17, 2006 (Date)

CC:

Signature of Person Mailing Correspondence

Mark J. Cohen

Typed or Printed Name of Person Mailing Correspondence

Doc Code:

PTO/SB/82 (04-05) Approved for use through 11/30/2005. OMB 0651-0035

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Red Clienter 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND

CHANGE OF CORRESPONDENCE ADDRESS

Application Number	09/595,218			
Filing Date	June 16, 2000			
First Named Inventor	Elfi Biedermann			
Art Unit	1625			
Examiner Name	Zinna Northington Davis			
Attorney Docket Number	19710			

I hereby revoke all previous powers of attorney given in the above-identified application:					n:		
A Power of Attorney is submitted herewith.							
OR	OR						
I hereby appoint the practitioners associated with the Customer Number: 00272							
✓ Please change the correspondence address for the above-identified application to:							
The address associated with Customer Number:							
OR							
Firm <i>or</i> Individual Name							
Address							
City		State		ZIP			
Country							
Telephone		Email					
l am the: Applicant/Inventor.							
Assignee of record of the entire interest. See 37 CFR 3.71 Statement under 37CFR 3.73(b) is enclosed. (Form PTO/SB/96)							
SIGNATURE of Applicant or Assignee of Record							
Signature							
Name Katrin Becker					1 22/2		
Date July 6, 2006		Telepho			14-2062		
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.							
☑ *Total of1 forms are submitted.							

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/96 (12-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the approver Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Doc GodalUL 2 1 2006

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Astellas Pharma GmbH				
Application No./Patent No./Control No.: 09/595,218	Filed/Issue Date: <u>June 16, 2000</u>			
Entitled: CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS				
Astellas Pharma GmbH , a Corpora	ntion			
(Name of Assignee) (Type of Assig	nee, e.g., corporation, partnership, university, government agency, etc.)			
states that it is:				
1. the assignee of the entire right, title, and interest; or				
2. an assignee of less than the entire right, title and interest The extent (by percentage) of its ownership interest is	%			
in the patent application/patent identified above by virtue of either:				
A. An assignment from the inventor(s) of the patent application/patent States Patent and Trademark Office at, Framis attached.				
OR				
B. A chain of title from the inventor(s), of the patent application/patent	identified above, to the current assignee as follows:			
From: To: The document was recorded in the United States Patent and Tradema Reel, Frame, or for which a content of the co				
2. From: To:				
The document was recorded in the United States Patent and Tradema Reel , Frame , or for which a c				
3. From: To:				
The document was recorded in the United States Patent and Tradema Reel , Frame , or for which a c				
Additional documents in the chain of title are listed on a supplemen				
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the cha or concurrently is being, submitted for recordation pursuant to 37 CFR 3 (NOTE: A separate copy (i.e., a true copy of the original assignment documents)	.11.			
The undersigned (whose title is supplied below) is authorized to act on behalf	July 6, 2006 Date			
Signature	Date			
Katrin Becker	+49 89 4544 -2062			
Printed or Typed Name	Telephone number			
Director Legal Affairs				
Title				

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ASSIGNMENT

WE, ELFI BIEDERMANN, residing in Vaterstetten, Germany; MAX HASMANN, residing in Neuried, Germany; ROLAND LÖSER, residing in Feldafing, Germany; BENNO RATTEL, residing in Munich, Germany; FRIEDEMANN REITER residing in Putzbrunn, Germany; BARBARA SCHEIN residing in Neufahrn, Germany; KLAUS SEIBEL residing in Grafelfing, Germany; KLAUS VOGT residing in Munich, Germany; KATJA WOSIKOWSKI residing in Poing, Germany; and ISABEL SCHMAINDA residing in Munich, Germany, for good and valuable consideration, receipt of which is hereby acknowledged, have assigned and do hereby assign to Klinge Pharma GmbH, having a principle place of business at Berg-am-Laim-Strasse 129, D-81673 Munich, Germany, its successors, assigns and legal representatives (Assignee), the entire right, title and interest in and to all subject matter invented by us and disclosed in U.S. Application No. 09/595,218, which is a continuation of International Patent Application No.~PCT/EP98/08267, filed 16 December 1998, entitled

CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL A CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS

and in and to all Patent and all Convention and Treaty rights of all kinds including the rights to claim priority therefrom, in the United States of America, for all such subject matter. We agree to sign all documents necessary to secure all said Patents and rights, and request issuance of all said Patents to the above assignee in accordance with this request.

25.10. , 2000	Elli Biodemnann
	Elfi Biedermann
25.10 , 2000	Max Hasmann

25.10. , 2000	2.2.ve
	Roland Löser
25.10. , 2000	B. 12
en de la companya de La companya de la co	Benno Rattel
25.10. 2000	Frein
	Friedemann Reiter
. 25.10. 2000	Rober She
	Barbara Schein
25.10 . 2000	I Sirbel
	Klaus Seibel
25.10. , 2000	John Vya
	Klaus Vogt
25.10. , 2000	Katja Wajkoushi
	Katja Wosikowski
25.10. , 2000	Martel Paremanide
- Andrews District Control of Con	Isabel Schemainda